1. Introduction {#s0005}
===============

The indirect, inhibitory action of numerous neurotransmitter molecules is mediated by G-protein activated inwardly rectifying potassium channels (GIRKs). GIRKs are triggered by G-protein coupled receptors (GPCRs) *via* G-protein α- and βγ-subunits. In electrically excitable tissue GIRKs contribute to autonomous regulation of the heartbeat, nociception and hormone secretion [@bb0005; @bb0010]. In electrically non-excitable tissues other important roles of GIRKs such as platelet activation [@bb0015], insulin secretion [@bb0020] and sperm function [@bb0025] have also been unravelled. According to this outstanding importance, single nucleotide polymorphisms or pathological mutations in one of the four human genes encoding GIRK subunit isoforms are causally related to various diseases, including primary aldosteronism and hypertension, alcohol abuse, atrial fibrillation, Andersen & Barter syndromes and congenital hyperinsulinism [@bb0030; @bb0035; @bb0040; @bb0045; @bb0050]. On the structural level functional GIRK channels are formed as homo- or heterotetrameric complexes [@bb0055]. The pore-forming tetramer is associated with G-protein α- and βγ-subunits, GPCRs coupling to different classes of G-proteins, protein kinases and -phosphatases, regulators of G-protein signalling, adenylate cyclase and cytoskeletal compounds in order to form membrane-subdomain localized signalling complexes with specific functional properties [@bb0060; @bb0065; @bb0070; @bb0075; @bb0080; @bb0085; @bb0090; @bb0095; @bb0100]. According to this complex supramolecular organisation, GIRK channels are not simply regulated by G-protein subunits alone, but additional regulatory pathways mediated by phosphatitylinositole-4,5-bisphosphate, protein kinases and Na^+^ ions, also exist [@bb0005]. GIRK channels, produced by homooligomeric GIRK2 and heterooligomeric GIRK1/GIRK2 or GIRK1/GIRK4 composition, were found to be regulated by cAMP dependent protein kinase (PKA; [@bb0105]). In the case of I~K + ACh~, the atrial GIRK1/GIRK4 complex, PKA phosphorylation was found to provide an "*on-switch"* for the activation of I~K + ACh~ by Gβγ itself, whereas protein phosphatase 2A (PP~2~A) generated GIRKs that were insensitive to Gβγ [@bb0110]. Our laboratory investigated this outstanding regulation at the single channel level [@bb0115] and later on succeeded to identify the structural determinant on the GIRK1 subunit in the form of three serine/threonines (S/Ts) within the cytosolic carboxyl-terminus (CT; [@bb0120; @bb0125]). So far, most GIRK complexes studied in the context of PKA regulation were of heterooligomeric nature. Therefore, the aim of the current study was to investigate whether GIRK4 subunits also participate in PKA mediated regulation of GIRK tetrameric complexes. Here we report that GIRK4 homooligomeric channels are regulated by PKA phosphorylation, identify two S/Ts within the GIRK4 structure that are responsible for the robust increase in both basal and agonist induced current and show that the GIRK4 subunit plays a significant role in the PKA regulation of heterooligomeric GIRK1/GIRK4 complexes.

2. Materials and methods {#s0010}
========================

2.1. Reagents {#s0025}
-------------

Glutathione Sepharose 4B was from GE Healthcare Europe GmbH, Vienna, Austria (27-4574-01). SpCAMPS and RpCAMPS were from Sigma-Aldrich, St. Louis, MO, USA (A166, A165, respectively). \[^32^P\]ATP\[γP\] was from GE Healthcare Europe GmbH, Vienna, Austria (25001748). Catalytic subunit of cAMP dependent protein kinase (PKA-cs) was purchased from Boehringer Ingelheim GmbH, Ingelheim, Germany (1529-307). All other reagents used were of reagent grade.

2.2. Solutions (concentrations in mmole.L^− 1^ unless stated otherwise) {#s0030}
-----------------------------------------------------------------------

Phosphorylation buffer (PhB): HEPES (25), MgCl~2~ (5), EGTA (5), Tween-20 (0.05%) buffered with NaOH to pH: 7.4. 4 × SDS loading buffer: Tris (400), sucrose (20% w/v), SDS (4% w/v), mercaptoethanole (20% v/v) titrated with HCl to pH: 6.8. Coomassie staining solution: Coomassie blue (0.04‰ w/v), methanol (50% v/v), acetic acid (10% v/v). Destain I: methanol (50% v/v), acetic acid (10% v/v). Destain II: methanol (5% v/v), acetic acid (7% v/v). ND96: NaCl (96), KCl (2), MgCl~2~ (1), CaCl~2~ (1), HEPES (5) buffered with NaOH to pH: 7.4. NDE: same as ND96 but CaCl~2~ was 1.8 and pyruvate (2.5) and antibiotics (0.1% v/v; from 1000 × stock from Sigma-Aldrich (G-1397)) were added. HK: KCl (96), NaCl (2), MgCl~2~ (1), CaCl~2~ (1), HEPES (5) buffered with KOH to pH: 7.4.

2.3. Genetic engineering {#s0035}
------------------------

Amplification of plasmids in bacteria, purification, linearization, ligation and site directed mutagenesis (using the DpnI method) were performed using standard procedures [@bb0130]. Plasmids with inserts encoding the different proteins have been already described: m~2~R [@bb0105], rGIRK1 & hGIRK4 [@bb0135]. cRNA was synthesised according to [@bb0140]. Phosphorylation deficient mutations of heterooligomeric rGIRK1^WT^ were produced using the identical primers as described for the homooligomeric rGIRK1^⁎^ construct [@bb0125]. The primers used for site directed mutagenesis of potential S/Ts within the hGIRK4 sequence are listed in supplementary Table S1. Plasmids for production of recombinant truncated intracellular regions of hGIRK4 fused to GST were produced according to [@bb0125] using suitable primers are listed in supplementary Table S2. All constructs and mutations were verified by sequencing.

2.4. Recombinant protein purification {#s0040}
-------------------------------------

Constructs were transfected into BL-21(RIL) competent cells (Stratagene, La Jolla, CA, USA). Overexpression and purification were achieved as previously described [@bb0145]. Purified recombinant protein was quantitated by the method of Bradford [@bb0150], diluted to a concentration of 1 μg. μL^− 1^, aliquots were shock frozen in liquid N~2~ and stored at − 70 °C until used.

2.5. *In-vitro* phosphorylation {#s0045}
-------------------------------

*In-vitro* phosphorylation of recombinant protein was performed as described [@bb0125]. Shortly, 1 μg protein was subjected to phosphorylation *in-vitro* by PKA-cs using \[^32^P\]ATP\[γP\] as co-substrate. Subsequently the protein was submitted to SDS-PAGE [@bb0155] on a 12% gel. Gels were stained with Coomassie blue, dried and scanned densitometrically. Quantitative autoradiography was performed using the Storm Phosphor imager (GE Healthcare Europe GmbH, Vienna, Austria). Incorporated radioactivity was normalized to the total amount of protein as detected by Coomassie stain (= relative specific radioactivity).

2.6. *Xenopus laevis* oocyte expression {#s0050}
---------------------------------------

The *Xenopus laevis* oocyte expression system was used exactly as described [@bb0160]. The amounts of RNA injected per oocyte are given in parenthesis (in ng per oocyte): m~2~R (2.5); GIRK1^WT^ (0.01--0.25); GIRK1^S385CS401CT407C^ (1); GIRK4^WT^ (0.01--2.5); GIRK4^⁎^ (0.01); GIRK4^⁎S75C^ (0.01); GIRK4^⁎S191C^ (0.165); GIRK4^⁎T199C^ (0.165); GIRK4^⁎S382C/A/E^ (0.01--10); GIRK4^⁎S412C^ (1); GIRK4^⁎S418A^ (0.01); GIRK4^⁎T199CS412C^ (1); GIRK4^S75C^ (0.25); GIRK4^T199C^ (0.165); GIRK4^S412C^ (0.165) and GIRK4^T199CS412C^ (1).

2.7. Electrophysiology {#s0055}
----------------------

Oocytes were studied following 3--5 day incubation at 19 °C in NDE. Superfusion with ND96 and HK (with and w/o 10^− 5^ mole/L acetylcholine) was performed at 21 °C while the membrane potential was set to − 80 mV and currents were recorded with the two electrode voltage clamp technique (TEVC) using agarose cushion electrodes [@bb0165] in connection with the Gene Clamp 500 amplifier (Molecular Devices Germany GmbH (Biberach an der Riss, Germany)). Cytosolic injections of cAMP and analogues (30--60 pmole per oocyte) during recording were performed as described [@bb0105]. The acute effect of cAMP injection was quantitated by normalizing the current increase, induced by cAMP injection (I~ACh~) to the basal current before cAMP injection was performed (I~HK~; see [Fig. 1](#f0010){ref-type="fig"}A for illustration). Thus, both in the case when cAMP was injected in the absence or in the presence of agonist, the cAMP effect is given by: $\frac{I_{\mathit{cAMP}}}{I_{\mathit{HK}}}$. Current traces were low pass filtered at 10 Hz and digitized at a sampling rate of 50 Hz using the digidata 1322A interface (Molecular Devices (Germany) GmbH, Biberach an der Riss, Germany) connected to a MS-Windows compatible computer using the pClamp9.2 software (Molecular Devices (Germany) GmbH, Biberach an der Riss, Germany).

2.8. Statistical analysis {#s0060}
-------------------------

Results from given experimental groups were compared for statistical significance using ANOVA or Student\'s *t*-Test, where appropriate (Sigma Plot 12.0; Systat Software Inc., San Jose, CA 95110 USA). In some instances, the calculated average value of current increase in percent was tested for a significant difference from zero by assuming Gaussian distribution [@bb0170].

3. Results {#s0015}
==========

3.1. Homooligomeric GIRK4 channel complexes are regulated by PKA {#s0065}
----------------------------------------------------------------

In order to investigate a potential contribution of the GIRK4 subunit, the homooligomeric mutation S143T [@bb0175] was introduced into the human GIRK4 sequence resulting in the human GIRK4^⁎^ subunit. GIRK4^⁎^ channels were expressed and studied in the *Xenopus laevis* oocyte expression system. Interestingly, cytosolic injections of cAMP led to a significant increase of both agonist induced and basal current through homooligomeric GIRK4^⁎^ channels ([Fig. 1](#f0010){ref-type="fig"}A). To further substantiate PKA catalysed phosphorylation as being responsible, the non-hydrolysable cAMP analogues SpCAMPS (activatory to PKA) and RpCAMPS (inhibitory to PKA) were injected. SpCAMPS, but not RpCAMPS, led to considerable augmentation of agonist induced currents, suggesting that PKA was responsible for the rapid and substantial effect caused by cAMP injections ([Fig. 1](#f0010){ref-type="fig"}B). Comparison of cAMP effects on GIRK1/GIRK4 complexes of different subunit composition revealed that both homooligomeric GIRK1^⁎^ (GIRK1^F137S^), GIRK4^⁎^ (GIRK4^S143T^) and GIRK4^WT^ complexes as well as heterooligomeric GIRK1^WT^/GIRK4^WT^ complexes were regulated by cAMP injection resulting in an increase of agonist as well as basal current ([Fig. 1](#f0010){ref-type="fig"}C). This finding is in line with previous results on the regulation of GIRK1/GIRK4 complexes by PKA, but indicates that the GIRK4 subunit may play an additional, hitherto unrecognized, role.

3.2. Identification of the structural determinant on the GIRK4 subunit {#s0070}
----------------------------------------------------------------------

Since GIRK4 channels revealed themselves susceptible to regulation by cAMP, it was of interest to investigate whether the cytosolic regions of GIRK4 subunits are targets for PKA mediated phosphorylation. Recombinant GST fusion proteins with the C- and the N-terminal regions of GIRK4 were used as substrates for phosphorylation by the catalytic subunit of PKA (PKA-cs) *in-vitro*. Both intracellular regions were identified to be substrates for this enzyme, the C-terminus being phosphorylated considerably stronger, when compared to the N-terminus ([Fig. 2](#f0015){ref-type="fig"}). This contrasts previous findings where exclusively the GIRK1, but not the GIRK4 subunit, was found to be a substrate for PKA [@bb0110]. In this case, however, the I~K + ACh~ complex was immunoprecipitated from bovine atrium. Besides species differences, a possible explanation for the failure to phosphorylate GIRK4 *in-vitro* could be high intrinsic levels of PKA phosphorylation in atrial tissue *per se* in contrast to the recombinant protein produced and purified by bacteria in the prevailing study. In order to more closely localize S/Ts responsible for PKA phosphorylation *in-vitro*, the GIRK4 C-terminus was further truncated into 4 smaller regions and subjected to PKA-cs phosphorylation *in-vitro*. In contrast to GIRK1, where the three S/Ts responsible for PKA phosphorylation are localized within a narrow stretch of no more than 22 amino acids within the C-terminus [@bb0125], phosphorylation sites within GIRK4 were dispersed all over the C-terminus, the proximal and distal parts being more prominently phosphorylated when compared to the intermediate region (supplementary Figs. S1A). S/Ts within the truncated fusion proteins complying to the PKA consensus sequence R/K-\[X\]~1--2~-S/T were mutated to cysteines (in some cases, when the introduction of artificial disulphide bonds was regarded to be a potential problem, the resulting point mutation was alanine). The mutant constructs were subjected to phosphorylation *in vitro* which was compared to the phosphorylation of the corresponding WT construct. In case the ^32^P incorporation of a mutant construct was still considerable, additional S/Ts other than the consensus were also mutated and the corresponding mutant construct subjected to phosphorylation, until its *in-vitro* phosphorylation was negligible. Finally, based on the effect of mutation of individual S/Ts within a construct, the relative contribution of each individual mutation to the phosphorylation of the entire cytosolic region (N--T plus C--T truncations) was calculated. Finally, four amino acids, T199, S382, S412 and S4128, contributed most prominently to the phosphorylation of the cytosolic parts of GIRK4 (supplementary Figs. S1B). In order to investigate whether T199, S382, S412 or S418 plays a functional role in the heterologous facilitation of GIRK currents by PKA, point mutations were introduced into the entire GIRK4^⁎^ sequence and the corresponding homooligomeric channel complex was tested for functional cAMP regulation. The N-terminal amino acids S75 and S191 (which had been reported to be essential for PKC regulation [@bb0180]) were mutated as controls. Mutation of S382 to C (or A or E) was lethal to channel function as we were unable to record significant currents from oocytes injected with GIRK4^⁎S382C(A,E)^ cRNA. When cRNA encoding a N-terminal fusion protein of eGFP and GIRK4^S143TS382C^ was injected into oocytes, no fluorescence could be detected, indicating that mutation of S382 prohibited GIRK4 synthesis (data not shown). Hence we were unable to study this S382 in further detail. From the remaining three amino acids, T199 and S412 exhibited profound and significant *ad hoc* effects on PKA regulation, while mutation S418A had no influence (see supplementary Figs. S2B). The impact of T199 and S412 on cAMP regulation was further investigated in the homooligomeric GIRK4^⁎^ complex. While single mutation of T199 almost completely abolished the effect of cAMP injections on agonist induced K^+^ currents, a single mutation of S412 also greatly reduced functional effects, when compared to WT. Hence we conclude that both amino acids contribute. Accordingly, simultaneous mutation of both amino acids led to homooligomeric channels that were completely insensitive to PKA modulation ([Fig. 3](#f0020){ref-type="fig"}). Since both T199 and S412 exerted profound and significant *ad hoc* effects upon PKA regulation, these two amino acids were mutated in the full-length C-terminal construct and the effect on *in vitro* phosphorylation was tested. Individual single mutations of T199 and S412 reduced the level of ^32^P incorporation catalysed by PKA-cs significantly and to a similar extent, while simultaneous mutation of the two amino acids abolished phosphorylation of the entire C--T almost completely ([Fig. 4](#f0025){ref-type="fig"}).

3.3. Molecular basis of the regulation of the heterooligomeric I~K + ACh~ complex by PKA {#s0075}
----------------------------------------------------------------------------------------

Since PKA catalyses the phosphorylation of both the GIRK1 and the GIRK4 subunits and both homooligomeric ion channel complexes are functionally affected by this enzyme, it was of interest to assess the role of each subunit type to the heterologous facilitation of the heterooligomeric I~K + ACh~ complex that plays an essential role in the regulation of the heartbeat by the autonomous nervous system [@bb0185], but presumably is also important in the central nervous system [@bb0190]. Combinations of *wild type* and phosphorylation deficient GIRK1^S385S401CT407C^ and GIRK4^T199CS412C^ subunits were coexpressed and their regulation by cAMP injections was compared. The importance of PKA catalysed phosphorylation of both subunits is underlined by the fact that incorporation of either the phosphorylation-deficient GIRK1^S385S401CT407C^ or the GIRK4^T199CS412C^ subunit into the heterooligomeric complex resulted in a considerable reduction of cAMP facilitation of currents, but it was still clearly detectable. Only GIRK1/4 complexes comprising both types of phosphorylation-deficient subunits were completely devoid of facilitation mediated by cAMP injection ([Fig. 5](#f0030){ref-type="fig"}). Hence we conclude that both subunits contribute to the heterologous facilitation of G-protein activation by PKA. At the molecular level five S/Ts, namely T199 and S412 on the GIRK4 subunit and S385, S401 and T407 on the GIRK1 subunit are required to produce the regulatory action.

4. Discussion {#s0020}
=============

The present study provides clear evidence that phosphorylation of the GIRK4 subunit plays an important role in the regulation of heterooligomeric GIRK1/GIRK4 channel complexes by PKA. PKA phosphorylation exerted robust stimulation of currents mediated by homooligomeric GIRK4 channels. Threonine-199 and serine-412 were identified as the structural determinant being responsible for ≈ 95% of phosphorylation of the cytosolic GIRK4 C-terminus catalysed by PKA *in-vitro* and ≈ 99% of the acute effect exerted by cAMP injections on homooligomeric GIRK4 channels *in-vivo*. Within the heterooligomeric GIRK1/GIRK4 complex, T199 and S412 contribute to ≈ 65% to the acute effect induced by PKA when coexpressed with the GIRK1^WT^ subunit. Acute PKA effects were practically absent (reduction to ≈ 3% *vs*. WTs) in heterotetrameric channels composed of both phosphorylation-deficient GIRK1 and GIRK4 subunits.

Specificity of S/T protein kinases is determined to a great extent by 3-D structure of the protein substrate and hence is completely understood in selected cases only [@bb0195]. In addition to 3-D structure, molecular determinants within the primary sequence near the target S/T exist that favour PKA phosphorylation. All 3 S/Ts that have been identified previously within the GIRK1 sequence [@bb0125] conform to the classical PKA consensus sequence --R/K~1--2~-X-S/T-, that is known to occur in about 95% of PKA substrates [@bb0200]. While T199 within GIRK4 also represents a "classical" PKA consensus sequence, S412 does not. According to [@bb0195] basic residues (R/K) at positions − 4 to − 7 can compensate, at least partially, for the lack of arginyl residues at positions − 2 and/or − 3 and indeed a K is located at position − 5 in the case of S412. Obviously K407, together with the 3-D structure of the GIRK4 C-T, renders S412 susceptible to PKA. Noteworthy, the nearby located S418 conforms to the classical consensus sequence described above and was phosphorylated by PKA-cs in our *in vitro* assay to an extent comparable to S412. Site-directed mutagenesis of S418 revealed, however, that this amino acid was not involved in the acute PKA effects described here. We conclude that S418 is either not phosphorylated by PKA *in-vivo* for reasons of 3-D structure or its phosphorylation is responsible, at least partially, for another hitherto unrecognized effect mediated by PKA.

Partial 3-D structures are available for GIRK1 [@bb0205; @bb0210] and GIRK2 [@bb0055]. Since the structures do not comprise the flexible distal C-termini where the determinants within GIRK1 and S412 of GIRK4 are located, it is at present not possible to understand mechanistically how PKA phosphorylation promotes GIRK activation by Gβγ *via* these S/Ts. T199, however, is covered by the crystal structures currently available and we may speculate about its mechanistical contribution to heterologous facilitation. The amino acid corresponding to T199 in GIRK4 is conserved throughout all four GIRK subunits (see [Fig. 6](#f0035){ref-type="fig"}) and lies within the trans membrane-domain/cytosolic-domain (TMD--CTD) linker that is essential for the control of GIRK1 and GIRK2 gating by G-proteins. According to the crystal structure of GIRK2, T204 contributes essentially to the stabilization of the closed conformation of the G-loop gate *via* a hydrogen bond with Y78 of the adjacent GIRK2 subunit. Since both amino acids are conserved between GIRK2 and GIRK4 (T199 and Y53 in GIRK4), the consequence of phosphorylation of T199 would be the disruption of Y53/T199 interaction what in turn would destabilize the G-loop gates closed conformation and promote its opening in GIRK4 homooligomeric channels.

Protein phosphorylation has been shown to play important roles in the regulation of GIRK channel function in physiology and pathophysiology. Several excitatory neurotransmitters, including glutamate, inhibit GIRKs *via* PTX insensitive G-proteins involving the PLC/PKC pathway [@bb0215; @bb0220]. The underlying mechanism has been identified as PKC-catalysed phosphorylation of two serines located in the cytosolic part of the GIRK1 and GIRK4 C-termini [@bb0180]. Another instance is the phosphorylation of serine 9 in the cytosolic N-terminus of GIRK2 *via* a protein kinase that is at present unknown. Protein phosphatase 1 mediated dephosphorylation of this serine results in increased surface localisation of GIRK2 at excitatory synapses and dendritic spines and represents an essential mechanism resulting in depotentiation of long term potentiation (LTP), an important form of excitatory synapse plasticity [@bb0225; @bb0230]. Regulation of GIRK1/GIRK4 heterooligomeric channels *via* PKA is at present well documented although its physiological role remains unidentified. In the case of atrial I~K + ACh~ one may speculate that the heterologous facilitation may represent a mechanism for stabilizing the membrane resting potential during increased speed of conduction and contractility that is required to prevent re-entry of excitation and fibrillation. Another, pathophysiological, function may be indicated by the ß-adrenergic stimulation of growth of cancer cells that has been shown to be linked to GIRK1 RNA expression [@bb0235]. GIRK1/GIRK4 channels are also known to exist in the CNS and sparse evidence about possible functional roles, derived from knockout mice, exists [@bb0190]. No data are hitherto available on possible roles of PKA regulation of GIRK1/GIRK4 channels in the brain.

Homooligomeric GIRK4 channel complexes have been shown to exist in native atrial tissue [@bb0240]. Functional single I~K + ACh~ channels presumably formed by GIRK4 homooligomers, but with aberrant kinetics and fast desensitisation, have been observed in atrial myocytes derived from GIRK1 k.o. mice [@bb0245]. Furthermore, Nikolov & Ivanova-Nikolova, were able to observe atypical small-conductance I~K + ACh~ channels in atrial myocytes, possibly formed by GIRK4 homooligomers that were regulated by PKA [@bb0250]. Regulation of homooligomeric GIRK4 channels may represent a potentially important physiological regulation mechanism in atrium but possibly also in other tissues.

Appendix A. Supplementary data {#s0080}
==============================

Supplementary material.
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![Homooligomeric GIRK4 channels are regulated by PKA.\
*A*.: Original current recording derived from an oocyte injected with cRNA encoding GIRK4 and m~2~R. Membrane potential was kept constant at − 80 mV. Basal current (I~HK~) was induced by changing from the physiological extracellular medium (ND96) to a medium containing 96 mmole/L K^+^ (HK). G-protein activation was achieved by perfusion with HK containing 10^− 5^ mole/L acetylcholine. An injection needle was inserted during agonist activation. In order to activate PKA 3 pmole cAMP were injected into the cytosol of the oocyte (both insertion and injection are indicated by an arrow). After washout of agonist and HK, both I~HK~ and I~ACh~ were elicited again in order to demonstrate the increase of currents through GIRK4 complexes.\
*B*.: Statistical analysis of the effect of injection of SpCAMPS, RpCAMPS and water on agonist induced currents through homooligomeric GIRK4^S143T^ complexes. Number of individual oocytes tested in parenthesis above each bar. \*\*: the mean value deviates statistically significant from both RpCAMPS and H~2~O at the p \< 0.01 level.\
*C*.: Statistical analysis of the effect of cAMP injection on basal currents and agonist induced currents through homooligomeric and heterooligomeric GIRK channel complexes. Number of individual oocytes tested in parenthesis above each bar. \*, (\*\*\*): the mean value deviates statistically significant from zero at the p \< 0.05 (0.001) level.](gr1){#f0010}

![Phosphorylation of the cytosolic regions of GIRK4 by PKA *in-vitro*.\
*A*.: *upper panel*: Autoradiogram showing ^32^P incorporation of the GIRK4 C- and N-terminal fusion proteins following incubation with PKA-cs and ATP-γ-^32^P. *Lower panel*: Coomassie stain of the electrophoresis gel shown in upper panel.\
*B*: Statistical analysis of ^32^P incorporation into N- and C-terminus. The number of individual phosphorylation experiments is shown in parenthesis above each bar. \*\*\*: the mean value deviates statistically significant from GST at the p \< 0.001 level.](gr2){#f0015}

![Role of T199 and S412 in the heterologous facilitation of homooligomeric GIRK4^⁎^ channels.\
*A*.: Original current recording derived from an oocyte injected with cRNA encoding GIRK4^⁎T199CS412C^ and m~2~R. Membrane potential was kept constant at − 80 mV. After induction of basal current (I~HK~) by superfusion with HK and G-protein activation by 10^− 5^ mole/L acetylcholine 5 pmole cAMP were injected into the cytosol oocyte (injection is indicated by an arrow).\
*B*.: Statistical analysis of the effect of cAMP injection on agonist induced currents through GIRK4^⁎^*WT* and mutant channels. Number of individual oocytes tested in parenthesis above each bar. \*\*\*: the mean value deviates statistically significant from GIRK4^⁎^*WT* at the p \< 0.001 level.](gr3){#f0020}

![Effect of T199 and S412 on PKA-cs catalysed ^32^P incorporation into the GIRK4 C-terminus.\
*A*.: *Upper panel*: Autoradiogram showing the effect of T199 and S412 on ^32^P incorporation into the GIRK4 C-terminal fusion protein (*upper panel*). *Lower panel*: Coomassie stain of the electrophoresis gel shown in upper panel.\
*B*.: Statistical analysis of ^32^P incorporation into *WT* and mutant forms of the GIRK4 C-terminus. The number of individual phosphorylation experiments is shown in parenthesis above each bar. \*\*\*: the mean value deviates statistically significant from zero at the p \< 0.001 level. §§§: the mean value deviates statistically significant from *WT* at the p \< 0.001 level.](gr4){#f0025}

![Role of individual subunits in the heterologous facilitation of heterooligomeric I~K,ACh~ channels.\
*A*: Original current recording derived from an oocyte injected with cRNA encoding GIRK1^WT^, GIRK4^WT^ and m~2~R. Membrane potential was kept constant at − 80 mV. After induction of basal current (I~HK~) by superfusion with HK, 4 pmole cAMP were injected into the cytosol of the oocyte (both insertion of needle and injection are indicated by an arrow).\
*B*: similar to 5 A, but the oocyte was injected with cRNA encoding the phosphorylation deficient GIRK1^S385CS401CT407C^ and GIRK4^T199CS412C^ subunits.\
*C*: Statistical analysis of the effect of cAMP injection on basal and agonist induced currents through heterooligomeric GIRK1/GIRK4 *WT* and mutant channel complexes. Number of individual oocytes tested in parenthesis above each bar. \*, (\*\*): the mean value deviates significantly from zero at the p \< 0.05 (0.01) level. §, (§§§): the mean value deviates statistically significant from GIRK1^WT^/GIRK4^WT^ at the p \< 0.05 (0.001) level.](gr5){#f0030}

![Primary structure alignment of the four GIRK subunit isoforms at the protein level.\
S/Ts in the GIRK4 sequence are highlighted in grey (italics: no major effect on phosphorylation *in-vitro*; italics/bold: major effect on phosphorylation *in-vitro*, but no functional consequence) or black (both profound effect on phosphorylation *in-vitro* and on heterologous facilitation). S/Ts that have been found to be important for heterologous facilitation in the GIRK1 sequence are also highlighted in black [@bb0125]. S191 that has been reported to be responsible for PKC regulation is marked in darker grey (both GIRK1 and GIRK4; [@bb0180]). Arrows indicate the truncations of the C-terminus used for phosphorylation *in vitro* (suppl. Figs. S1). TM1, TM2 and P denote the trans membrane and the pore helices, respectively.](gr6){#f0035}
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